Ehave Solutions Gain Traction in Cannabis Industry
Ryan Allway
March 7th, 2018
Exclusive, News, Top News
The cannabis industry is expected to reach $50 billion by 2022 in the U.S. alone, according to Cowen & Co., driven by a growing number of states that have legalized the drug for medical and adult use. At the same time, a growing number of researchers have become interested in the drug as a potential treatment for a wide range of medical conditions. The problem is that its difficult to keep effective records in cannabis clinical trials.
Ehave Inc.’s (OTCQB: EHVVF) Connect platform is an innovative bioinformatics tool that enables researchers, physicians, and patients to connect in a way that was never before possible. By bringing all of these parties together, everyone can work towards the common goal of improving patient outcomes on a highly personalized level.
Revive Therapeutics Collaboration
Ehave recently announced a collaboration agreement with Revive Therapeutics Ltd. (TSX-V: RVV) (OTCQB: RVVTF) to provide enhanced patient and clinical research data management. Under the terms of the agreement, Revive will integrate the Ehave Connect platform with its ongoing research involving the use of medical cannabis for the treatment of liver diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and fibrosis.
“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Revive CEO Craig Leon. “Ehave’s platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research.”
The Ehave Connect platform collects and integrates patient data from clinical systems, licensed health surveys, and patient and clinician reported outcomes. By keeping patients engaged throughout the healthcare journey, the platform helps connect teams across disciplines and ensure that patients have the best treatments and options available to them.
“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular, companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” said Ehave CEO Prateek Dwivedi.
Aequus Pharma’s Clinical Trials
Ehave announced a collaboration with Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) just a week after its agreement with Revive. Under that agreement, Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying cannabinoid-rich formulations for treating a number of neurological disorders.
“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original letter of intent with Ehave,” said Aequus CEO Doug Janzen. “We have a number of different clinical trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs [in the cannabis space].”
The agreement involves Aequus paying Ehave a per-patient fee for trials conducted using its Ehave Connect platform. In return, Aequus will receive patient assessment, diagnostic, and therapeutic outcomes and side-effect profile content from formal and informal studies conducted using the platform. Aequus will also fully own all clinical results and data generated from trials using the Ehave Connect platform.
“Our robust bioinformatics platform allows us to provide customized, next generation clinical solutions that empower pharmaceutical developers such as Aequus to be successful,” said Ehave CEO Prateek Dwivedi. “We look forward to helping them advance their clinical programs and potentially improve outcomes for patients with neurological disorders who may benefit from Aequus’ products.”
Looking Ahead
Ehave Inc. (OTCQB: EHVVF) represents a compelling investment opportunity in the pharmaceutical and cannabis industries. With two new partnerships in March, the company has demonstrated its ability to execute its plan to become a leading platform for the research and development of cannabinoid therapeutics. Investors may want to take a closer look at the stock as it ramps up its commercialization with these new license agreements.
For more information, visit the company’s website at www.ehave.com.
Disclaimer
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada . Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.
Plus Products, through its wholly-owned subsidiary, Carberry, operates as a branded cannabis products manufacturer with operations in California.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
